Cited by 372Liver Disease Diagnosis and TreatmentLiver Diseases and ImmunityLiver physiology and pathology

The DOI matches its Crossref record; 25 of the 28 references it cites were found in a registry or an index.

Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease

Open access

Kleiner, David E., Brunt, Elizabeth M., Wilson, Laura A., Behling, Cynthia, Guy, Cynthia, Contos, Melissa, Cummings, Oscar, Yeh, Matthew, Gill, Ryan, Chalasani, Naga, Neuschwander-Tetri, Brent A., Diehl, Anna Mae, Dasarathy, Srinivasan, Terrault, Norah, Kowdley, Kris, Loomba, Rohit, Belt, Patricia, Tonascia, James, Lavine, Joel E., Sanyal, Arun J., for the Nonalcoholic Steatohepatitis Clinical Research Network·2019·JAMA Network Open

DOI 10.1001/jamanetworkopen.2019.12565PMC PMC6784786

Open this paper in CoChat — free account Open PDF

Abstract

Importance: The histologic evolution of the full spectrum of nonalcoholic fatty liver disease (NAFLD) and factors associated with progression or regression remain to be definitively established. Objective: To evaluate the histologic evolution of NAFLD and the factors associated with changes in disease severity over time. Design, Setting, and Participants: A prospective cohort substudy from the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) NAFLD Database study, a noninterventional registry, was performed at 8 university medical research centers. Masked assessment of liver histologic specimens was performed, using a prespecified protocol to score individual biopsies. Participants included 446 adults with NAFLD enrolled in the NASH CRN Database studies between October 27, 2004, and September 13, 2013, who underwent 2 liver biopsies 1 or more year apart. Data analysis was performed from October 2016 to October 2018. Main Outcomes and Measures: Progression and regression of fibrosis stage, using clinical, laboratory, and histologic findings, including the NAFLD activity score (NAS) (sum of scores for steatosis, lobular inflammation, and ballooning; range, 0-8, with 8 indicating more severe disease). Results: A total of 446 adults (mean [SD] age, 47 [11] years; 294 [65.9%] women) with NAFLD (NAFL, 86 [19.3%]), borderline NASH (84 [18.8%]), and definite NASH (276 [61.9%]) were studied. Over a mean (SD) interval of 4.9 (2.8) years between biopsies, NAFL resolved in 11 patients (12.8%) and progressed to steatohepatitis in 36 patients (41.9%). Steatohepatitis resolved in 24 (28.6%) of the patients with borderline NASH and 61 (22.1%) of those with definite NASH. Fibrosis progression or regression by at least 1 stage occurred in 132 (30%) and 151 [34%] participants, respectively. Metabolic syndrome (20 [95%] vs 108 [72%]; P = .03), baseline NAS (mean [SD], 5.0 [1.4] vs 4.3 [1.6]; P = .005), and smaller reduction in NAS (-0.2 [2] vs -0.9 [2]; P < .001) were associated with progression to advanced (stage 3-4) fibrosis vs those without progression to stage 3 to 4 fibrosis. Fibrosis regression was associated with lower baseline insulin level (20 vs 33 μU/mL; P = .02) and decrease in all NAS components (steatosis grade -0.8 [0.1] vs -0.3 [0.9]; P < .001; lobular inflammation -0.5 [0.8] vs -0.2 [0.9]; P < .001; ballooning -0.7 [1.1] vs -0.1 [0.9]; P < .001). Only baseline aspartate aminotransferase (AST) levels were associated with fibrosis regression vs no change and progression vs no change on multivariable regression: baseline AST (regression: conditional odds ratio [cOR], 0.6 per 10 U/L AST; 95% CI, 0.4-0.7; P < .001; progression: cOR, 1.3; 95% CI, 1.1-1.5; P = .002). Changes in the AST level, alanine aminotransferase (ALT) level, and NAS were also associated with fibrosis regression and progression (ΔAST level: regression, cOR, 0.9; 95% CI, 0.6-1.2; P = .47; progression, cOR, 1.3; 95% CI, 1.0-1.6; P = .02; ΔALT level: regression, cOR, 0.7 per 10 U/L AST; 95% CI, 0.5-0.9; P = .002; progression, cOR, 1.0 per 10 U/L AST; 95% CI, 0.9-1.2; P = .93; ΔNAS: regression, cOR, 0.7; 95% CI, 0.6-0.9; P = .001; progression, cOR, 1.3; 95% CI, 1.1-1.5; P = .01). Conclusions and Relevance: Improvement or worsening of disease activity may be associated with fibrosis regression or progression, respectively, in NAFLD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jamanetworkopen.2019.12565

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A new look at the statistical model identification
Akaike, H. (1974) · IEEE Transactions on Automatic Control · doi:10.1109/tac.1974.1100705 · Cited by 51,879
Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption‐II
SAUNDERS, J. B., AASLAND, O. G., BABOR, T. F., DE LA FUENTE, J. R., & GRANT, M. (1993) · Addiction · doi:10.1111/j.1360-0443.1993.tb02093.x · Cited by 13,597 · cited 3×
“Individuals whose biopsies demonstrated definite NASH, compared with those with NAFL, were older (mean [SD], 49 [11] vs 45 [11] years; P = .”
BackgroundInfluential
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citation
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citation
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citation
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Self-citation
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies
Singh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
Self-citation

Flagged first, then by citations

Show all 28 references

3 of the 28 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 372

Efficacy and safety of semaglutide in non-alcoholic fatty liver disease
Zhu, K., Kakkar, R., Chahal, D., Yoshida, E. M., & Hussaini, T. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i37.5327 · Cited by 57
Natural History of NAFLD
Pais, R., & Maurel, T. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10061161 · Cited by 47
Immune–metabolic interactions in homeostasis and the progression to NASH
Hoogerland, J. A., Staels, B., & Dombrowicz, D. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.07.001 · Cited by 46
Liver biopsy evaluation in MASH drug development: Think thrice, act wise
Harrison, S. A., & Dubourg, J. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.008 · Cited by 45
Controversies and Opportunities in the Use of Inflammatory Markers for Diagnosis or Risk Prediction in Fatty Liver Disease
Lambrecht, J., & Tacke, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.634409 · Cited by 46
Obeticholic acid for the treatment of nonalcoholic steatohepatitis
Shah, R. A., & Kowdley, K. V. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1748498 · Cited by 44
Self-citation
Preparing for the NASH epidemic: A call to action
Kanwal, F., Shubrook, J. H., Younossi, Z. M., Natarajan, Y., Bugianesi, E., Rinella, M. E., Harrison, S. A., Mantzoros, C. S., Pfotenhauer, K. M., Klein, S., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154822 · Cited by 46
Deep learning and digital pathology powers prediction of HCC development in steatotic liver disease
Nakatsuka, T., Tateishi, R., Sato, M., Hashizume, N., Kamada, A., Nakano, H., Kabeya, Y., Yonezawa, S., Irie, R., Tsujikawa, H., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000904 · Cited by 42
On the Proposed Definition of Metabolic-Associated Fatty Liver Disease
Wong, V. W., & Kanwal, F. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.01.017 · Cited by 42
Treatment Candidacy for Pharmacologic Therapies for NASH
Rowe, I. A., Wong, V. W.-S., & Loomba, R. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.03.005 · Cited by 41
Self-citation
Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study
Simon, T. G., Ebrahimi, F., Roelstraete, B., Hagström, H., Sundström, J., & Ludvigsson, J. F. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02070-5 · Cited by 41
Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort study
Simon, T. G., Roelstraete, B., Hagström, H., Loomba, R. S., & Ludvigsson, J. F. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.08.008 · Cited by 40
Self-citation
Non-invasive lipid panel of MASLD fibrosis transition underscores the role of lipoprotein sulfatides in hepatic immunomodulation
Lam, S. M., Wang, Z., Song, J., Shi, Y., Liu, W., Wan, L., Duan, K., Chua, G. H., Zhou, Y., Wang, G., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.09.009 · Cited by 45
Non-alcoholic fatty liver disease: A review with clinical and pathological correlation
Chen, Y., & Yeh, M. M. (2020) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2020.07.006 · Cited by 39
Self-citation
Nonalcoholic fatty liver disease and non-liver comorbidities
Manikat, R., & Nguyen, M. H. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0442 · Cited by 37
Digital pathology for nonalcoholic steatohepatitis assessment
Sanyal, A. J., Jha, P., & Kleiner, D. E. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00843-7 · Cited by 39
Self-citation
Efficacy and Safety of Fibroblast Growth Factor‐21 Analogs for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis: A Systematic Review and Meta‐Analysis
Jeong, C., Han, N., Jeon, N., Rhee, S., Staatz, C. E., Kim, M., & Baek, I. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3278 · Cited by 36
Non-alcoholic fatty liver disease: a multi-system disease influenced by ageing and sex, and affected by adipose tissue and intestinal function
Bilson, J., Sethi, J. K., & Byrne, C. D. (2021) · Proceedings of The Nutrition Society · doi:10.1017/s0029665121003815 · Cited by 37
Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes
Ajmera, V. H., Tesfai, K., Sandoval, E., Lopez, S. J., Cervantes, V., Madamba, E. V., Bettencourt, R., Manousou, P., Richards, L., & Loomba, R. S. (2023) · Hepatology · doi:10.1097/hep.0000000000000635 · Cited by 36
Self-citation
A roadmap for clinical trials in MASH-related compensated cirrhosis
Pericàs, J. M., Anstee, Q. M., Augustín, S., Bataller, R. A., Berzigotti, A., Ciudin, A., Francque, S., Abraldeṣ, J. G., Hernández–Gea, V., Pons, M., et al. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00955-8 · Cited by 38
Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2–F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study
Wong, V. W., Amin, N. B., Takahashi, H., Darekar, A., Tacke, F., Kiszko, J., Rodriguez, H., Nakajima, A., Alkhouri, N., Charlton, M., et al. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00128-1 · Cited by 37
Endpoints in NASH Clinical Trials: Are We Blind in One Eye?
Lonardo, A., Ballestri, S., Mantovani, A., Targher, G., & Bril, F. (2024) · Metabolites · doi:10.3390/metabo14010040 · Cited by 34
Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus–Associated Nonalcoholic Fatty Liver Disease
Fourman, L. T., Stanley, T. L., Zheng, I., Pan, C. S., Feldpausch, M. N., Purdy, J., Aepfelbacher, J., Buckless, C. G., Tsao, A., Corey, K. E., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa382 · Cited by 34
Self-citation
Hepatic Steatosis and Steatohepatitis in a Large North American Cohort of Adults With Chronic Hepatitis B
Khalili, M., Kleiner, D. E., King, W. C., Sterling, R. K., Ghany, M. G., Chung, R. T., Bhan, A. K., Rosenthal, P. J., Lisker‐Melman, M., Ramachandran, R., et al. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001257 · Cited by 34
Self-citation
Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso)
Moreira, R. O., Valério, C. M., Villela‐Nogueira, C. A., Cercato, C., Gerchman, F., Lottenberg, A. M., Godoy‐Matos, A. F., Oliveira, R. D. A., Brandão‐Mello, C. E., Álvares‐da‐Silva, M. R., et al. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2023-0123 · Cited by 45
Prevalence, Diagnosis, and Treatment with 3 Different Statins of Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?
Sfikas, G., Psallas, M., Koumaras, C., Imprialos, K. P., Perdikakis, E., Doumas, M. N., Γιουλεμέ, Ό., Karagiannis, A. I., & Athyros, V. G. (2020) · Current Vascular Pharmacology · doi:10.2174/1570161118666201015152921 · Cited by 33
NAFLD-related mortality: simple hepatic steatosis is not as ‘benign’ as thought
Tilg, H., & Targher, G. (2020) · Gut · doi:10.1136/gutjnl-2020-323188 · Cited by 32
MRI-AST (MAST) Score Accurately Predicts Major Adverse Liver Outcome, Hepatocellular Carcinoma, Liver Transplant, and Liver-Related Death
Truong, E., GORNBEIN, J. A., Yang, J. D., Noureddin, N., Harrison, S. A., Alkhouri, N., & Noureddin, M. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.02.003 · Cited by 33
A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K. J., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A., & Harrison, S. A. (2021) · Yearbook of pediatric endocrinology · doi:10.1530/ey.18.15.7 · Cited by 33
Self-citation
Hepatic Outcomes of Nonalcoholic Fatty Liver Disease Including Cirrhosis and Hepatocellular Carcinoma
Alqahtani, S. A., Chan, W., & Yu, M. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.019 · Cited by 32
Changing trends of liver transplantation and mortality from non-alcoholic fatty liver disease
Majumdar, A., & Tsochatzis, E. A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154291 · Cited by 32
A practical use of noninvasive tests in clinical practice to identify high‐risk patients with nonalcoholic steatohepatitis
Younossi, Z. M., Alkhouri, N., Cusi, K., Isaacs, S. D., Kanwal, F., Noureddin, M., Loomba, R. S., Ravendhran, N., Lam, B. P., Nader, K., et al. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17346 · Cited by 31
Self-citation
Emerging trends and hotspots in metabolic dysfunction-associated fatty liver disease (MAFLD) research from 2012 to 2021: A bibliometric analysis
Liao, Y., Wang, L., Liu, F., Zhou, Y., Lin, X., Zhao, Z., Xu, S., Tang, D., Jiao, Y., Yang, L., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1078149 · Cited by 32
Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease
Hu, Y., Sun, C., Chen, Y., Liu, Y., & Fan, J. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00123 · Cited by 34
Cell Autophagy in NASH and NASH-Related Hepatocellular Carcinoma
Udoh, U. S., Rajan, P. K., Nakafuku, Y., Finley, R., & Sanabria, J. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147734 · Cited by 30
Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH
Li, J., Lu, X., Zhu, Z. H., Kalutkiewicz, K. J., Mounajjed, T., Therneau, T. M., Venkatesh, S. K., Sui, Y., Glaser, K. J., Hoodeshenas, S., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000417 · Cited by 30
Probiotic supplementation for 24 weeks in patients with non-alcoholic steatohepatitis: the PROBILIVER randomized clinical trial
Silva-Sperb, A. S., Moraes, H. A., Barcelos, S. T. A., de Moura, B. C., Longo, L., Michalczuk, M. T., Cerski, C. T. S., Cruz, C. U., da Silveira, T. R., Álvares‐da‐Silva, M. R., et al. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1362694 · Cited by 29
Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination
Blank, V., Petroff, D., Beer, S., Böhlig, A., Heni, M., Berg, T., Bausback, Y., Dietrich, A., Tönjes, A., Hollenbach, M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-75227-x · Cited by 29
Non-Alcoholic Fatty Liver Disease in HIV/HBV Patients – a Metabolic Imbalance Aggravated by Antiretroviral Therapy and Perpetuated by the Hepatokine/Adipokine Axis Breakdown
Iacob, S. A., & Iacob, D. G. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.814209 · Cited by 27
Liver histology is associated with long-term clinical outcomes in patients with metabolic dysfunction–associated steatohepatitis
Younossi, Z. M., Mangla, K. K., Berentzen, T. L., Grau, K., Kjær, M. S., Ladelund, S., Nitze, L. M., Coolbaugh, C. L., Hsu, C.-Y., & Hagström, H. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000423 · Cited by 30
FIB-4 as a screening and disease monitoring method in pre-fibrotic stages of metabolic dysfunction-associated fatty liver disease (MASLD)
Albert, S. G., & Wood, E. M. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108777 · Cited by 30
Increased Adherence to the Mediterranean Diet after Lifestyle Intervention Improves Oxidative and Inflammatory Status in Patients with Non-Alcoholic Fatty Liver Disease
Monserrat-Mesquida, M., Quetglas‐Llabrés, M. M., Bouzas, C., Montemayor, S., Mascaró, C. M., Casares, M., Llompart, I., Ugarriza, L., Martínez, J. A., Tur, J. A., et al. (2022) · Antioxidants · doi:10.3390/antiox11081440 · Cited by 31
Prevalence of at-risk NASH and its association with metabolic syndrome in US adults with NAFLD, 2017–2018
Payne, J. Y., Alkhouri, N., Le, P., Rothberg, M. B., Polanco, P., Sakkal, C., & Dasarathy, S. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000019 · Cited by 28
Self-citation
NAFLD No More: A Review of Current Guidelines in the Diagnosis and Evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Kaylan, K. B., & Paul, S. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01558-y · Cited by 27
Pathologic Diagnosis of Nonalcoholic Fatty Liver Disease
Lai, J., Wang, H. L., Zhang, X., Wang, H., & Liu, X. (2021) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2021-0339-ra · Cited by 27
The nonalcoholic steatohepatitis extended hepatocyte ballooning score: histologic classification and clinical significance
Gill, R. M., Allende, D. S., Belt, P. H., Behling, C. A., Cummings, O. W., Guy, C. D., Carpenter, D., Neuschwander‐Tetri, B. A., Sanyal, A. J., Tonascia, J. A., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000033 · Cited by 27
Self-citation
Agents for the treatment of fatty liver disease: focus on essential phospholipids
Dajani, A. I., & Abu-Hammour, A. (2021) · Drugs & Therapy Perspectives · doi:10.1007/s40267-021-00838-x · Cited by 26
At the Crossroads of Health and Disease: Consequences of Fat in the Liver
Dukewich, M., Yuan, L., & Terrault, N. A. (2025) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022724-105515 · Cited by 35
Self-citation
The impact of genetic risk on liver fibrosis in non‐alcoholic fatty liver disease as assessed by magnetic resonance elastography
Ajmera, V. H., Liu, A. Y., Bettencourt, R., Dhar, D., Richards, L., & Loomba, R. S. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16392 · Cited by 25
Self-citation
What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?
Alkhouri, N., Tincopa, M. A., Loomba, R. S., & Harrison, S. A. (2021) · Hepatology Communications · doi:10.1002/hep4.1814 · Cited by 27
Self-citation
Fat and Sugar—A Dangerous Duet. A Comparative Review on Metabolic Remodeling in Rodent Models of Nonalcoholic Fatty Liver Disease
Simões, I. C. M., Janikiewicz, J., Bauer, J., Karkucińska‐Więckowska, A., Kalinowski, P., Dobrzyń, A., Wolski, A., Pronicki, M., Zieniewicz, K., Dobrzyń, P., et al. (2019) · Nutrients · doi:10.3390/nu11122871 · Cited by 27
Present and Future Perspectives in the Treatment of Liver Fibrosis
Cerrito, L., Galasso, L., Iaccarino, J., Pizzi, A., Termite, F., Esposto, G., Borriello, R., Ainora, M. E., Gasbarrini, A., & Zocco, M. A. (2025) · Pharmaceuticals · doi:10.3390/ph18091321 · Cited by 29
Efficacy and safety of drugs for nonalcoholic steatohepatitis
Shen, B., & Lu, L. (2021) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12967 · Cited by 24
Genetic Factors Associated with Response to Vitamin E Treatment in NAFLD
Civelek, M., & Podszun, M. C. (2022) · Antioxidants · doi:10.3390/antiox11071284 · Cited by 25
Improvement in insulin sensitivity and prevention of high fat diet-induced liver pathology using a CXCR2 antagonist
Phillips, B. E., Lantier, L., Engman, C., Garciafigueroa, Y., Singhi, A. D., Trucco, M., Mantzoros, C. S., Wasserman, D. H., & Giannoukakis, N. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01564-y · Cited by 24
Emerging pharmacological treatment options for MAFLD
Rojas, Á., Lara, C., Múñoz‐Hernández, R., Gato, S., Ampuero, J., & Romero‐Gómez, M. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221142452 · Cited by 59
MAFLD in adults: non-invasive tests for diagnosis and monitoring of MAFLD
Chan, W., Wong, V. W., Adams, L. A., & Nguyen, M. H. (2024) · Hepatology International · doi:10.1007/s12072-024-10661-x · Cited by 24
Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease
Ikeda, S., Sugihara, T., Hoshino, Y., Matsuki, Y., Nagahara, T., Okano, J., Kitao, S., Fujioka, Y., Yamamoto, K., & Isomoto, H. (2020) · Yonago acta medica · doi:10.33160/yam.2020.08.009 · Cited by 25
Metabolic Dysfunction-Associated Steatotic Liver Disease: A Silent Driver of Cardiovascular Risk and a New Target for Intervention
Gallo, G., Nalli, G., Baratta, F., Desideri, G., & Savoia, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26168081 · Cited by 27
Prevalence and clinical significance of portal inflammation, portal plasma cells, interface hepatitis and biliary injury in liver biopsies from patients with non-alcoholic steatohepatitis
Dhingra, S., Mahadik, J. D., Tarabishy, Y., May, S., & Vierling, J. M. (2022) · Pathology · doi:10.1016/j.pathol.2022.01.009 · Cited by 23
Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis
Pennisi, G., Celsa, C., Enea, M., Vaccaro, M., Marco, V. D., Ciccioli, C., Infantino, G., Mantia, C. L., Parisi, S., Vernuccio, F., et al. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.07.001 · Cited by 23
The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes
Bridi, L., Agrawal, S., Tesfai, K., Madamba, E. V., Bettencourt, R., Richards, L., Khera, A. V., Loomba, R. S., & Ajmera, V. H. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18099 · Cited by 23
Self-citation
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 29
Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications
Hydes, T., Brown, E. E., Hamid, A., Bateman, A. C., & Cuthbertson, D. J. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.07.012 · Cited by 22
Efficacy and Safety of a Botanical Formula Fuzheng Huayu for Hepatic Fibrosis in Patients with CHC: Results of a Phase 2 Clinical Trial
Hassanein, T., Tai, D., Liu, C., Box, T. D., Tong, M. J., Rossaro, L., Pozza, R., Glenn, J. S., Cheung, R. C., Hemaidan, A., et al. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/4494099 · Cited by 23
Self-citation
Maternal Western diet is associated with distinct preclinical pediatric NAFLD phenotypes in juvenile nonhuman primate offspring
Nash, M. J., Dobrinskikh, E., Janssen, R. C., Lovell, M. A., Schady, D. A., Levek, C., Jones, K. L., D’Alessandro, A., Kievit, P., Aagaard, K. M., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000014 · Cited by 21
Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
Euh, W., Lim, S. K., & Kim, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.613389 · Cited by 23
The Combination of MR Elastography and Proton Density Fat Fraction Improves Diagnosis of Nonalcoholic Steatohepatitis
Alsaqal, S., Hockings, P. D., Ahlström, H. K., Gummesson, A., Hedström, A., Hulthe, J., Johansson, L., Niessen, H. G., Schoelch, C., Schultheis, C., et al. (2021) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.28040 · Cited by 22
An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical Trials
Leow, W. Q., Bédossa, P., Liu, F., Wei, L., Lim, K., Wan, W., Ren, Y., Chang, J. P.-E., Tan, C., Wee, A., et al. (2020) · Diagnostics · doi:10.3390/diagnostics10090643 · Cited by 21
Hidden in the Fat: Unpacking the Metabolic Tango Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Syndrome
Boulos, M., Mousa, R. S., Jeries, N., Simaan, E., Alam, K., Bulus, B., & Assy, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073448 · Cited by 22
Genetic and non-genetic drivers of histological progression and regression in MASLD
Gómez, E. V., Yates, K. P., Kleiner, D. E., Behling, C. A., Cummings, O. W., Wilson, L., Liang, T., Jarasvaraparn, C., Loomba, R., Schwimmer, J. B., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.09.013 · Cited by 23
Self-citation
Consensus position statements for the standardized application of histological grading and staging systems in MASH clinical trials
Lackner, C., Gouw, A. S. H., Alves, V. A. F., Arola, J. T., Bédossa, P., Behling, C. A., Brunt, E. M., Burt, A. D., Clouston, A. D., Cummings, O. W., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.09.019 · Cited by 19
Self-citation
Impact of a Novel Digital Therapeutics System on Nonalcoholic Steatohepatitis: The NASH App Clinical Trial
Sato, M., Akamatsu, M., Shima, T., Ikegami, T., Yanase, M., Mikami, S., Imamura, J., Nakatsuka, T., Tateishi, R., Yamauchi, N., et al. (2022) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002143 · Cited by 20
ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trial
Hu, Y., Li, H., Zhang, H., Chen, X., Chen, J., Xu, Z., You, H., Dong, R., Peng, Y., Li, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42162-0 · Cited by 23
Clinical Utility of Change in Nonalcoholic Fatty Liver Disease Activity Score and Change in Fibrosis in NAFLD
Tamaki, N., Munaganuru, N., Jung, J., Yonan, A. Q., Bettencourt, R., Ajmera, V. H., Valasek, M. A., Behling, C. A., & Loomba, R. S. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.11.005 · Cited by 20
Self-citation
ASMBS Position Statement on the Impact of Metabolic and Bariatric Surgery on Nonalcoholic Steatohepatitis
Mazzini, G. S., Augustin, T., Noria, S. F., Romero‐Marrero, C., Li, N., Hameed, B., Eisenberg, D., Azagury, D. E., & Ikramuddin, S. (2021) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2021.11.015 · Cited by 20
The use of current knowledge and non‐invasive testing modalities for predicting at‐risk non‐alcoholic steatohepatitis and assessing fibrosis
Kugelmas, M., Noureddin, M., Gunn, N., Brown, K., Younossi, Z. M., Abdelmalek, M. F., & Alkhouri, N. (2023) · Liver International · doi:10.1111/liv.15555 · Cited by 18
Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 study
Sanyal, A. J., Loomba, R. S., Anstee, Q. M., Ratziu, V., Kowdley, K. V., Rinella, M. E., Harrison, S. A., Resnick, M. B., Capozza, T. A., Sawhney, S., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000325 · Cited by 19
Self-citation
Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management
Adinolfi, L. E., Marrone, A., Rinaldi, L., Nevola, R., Izzi, A., & Sasso, F. C. (2025) · Exploration of Medicine · doi:10.37349/emed.2025.1001281 · Cited by 18
Noninvasive pathway for stratifying fibrosis in suspected metabolic dysfunction and alcohol-associated liver disease (MetALD)
Díaz, L. A., Tavaglione, F., Mittal, N., Bettencourt, R., Amangurbanova, M., Johnson, A., Aguado, D. M., Tincopa, M. A., Loomba, R. K., Khan-Riches, A., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000718 · Cited by 19
Self-citation
LncPRYP4-3 serves as a novel diagnostic biomarker for dissecting subtypes of metabolic associated fatty liver disease by targeting RPS4Y2
Yang, H., Li, Q., Zhang, L., Zhu, M. J., Niu, J., Xue, F., Yang, L., Qu, Q., Lao, Y., Ding, Z., et al. (2020) · Clinical and Experimental Medicine · doi:10.1007/s10238-020-00636-1 · Cited by 18
Digital Pathology Enables Automated and Quantitative Assessment of Inflammatory Activity in Patients with Chronic Liver Disease
Aguado, D. M., Fernández-Patón, M., Alfaro‐Cervelló, C., Mestre‐Alagarda, C., Bauza, M. E., Gallén-Peris, A., Merino, V., Benlloch, S., Pérez‐Rojas, J., Ferrández, A., et al. (2021) · Biomolecules · doi:10.3390/biom11121808 · Cited by 18
Clinical impact and mechanisms of hepatitis B virus infection concurrent with non-alcoholic fatty liver disease
Tong, X., Song, Y., Yin, S., Wang, J., Huang, R., Wu, C., Shi, J., & Li, J. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002310 · Cited by 19
Liver biopsy reliability in clinical trials: Thoughts from a liver pathologist
Brunt, E. M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.014 · Cited by 19
Self-citation
Real‐World Assessment of Liver Corrected T1 and Magnetic Resonance Elastography in Predicting Liver Disease Progression
Corey, K. E., Nakrour, N., Bethea, E. D., Shay, J. E. S., Andersson, K. L., Bhan, I., Friedman, L. S., Kambadakone, A. R., Dichtel, L. E., Chung, R. T., et al. (2025) · Liver International · doi:10.1111/liv.70280 · Cited by 18
Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma
Cernea, S., & Onișor, D. M. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i2.286 · Cited by 18
Banting memorial lecture 2022: ‘Type 2 diabetes and nonalcoholic fatty liver disease: Partners in crime’
Byrne, C. D. (2022) · Diabetic Medicine · doi:10.1111/dme.14912 · Cited by 17
Three-Dimensional Vector MR Elastography for Evaluating Tissue Mechanical Heterogeneity to Assess Liver Disease Progression
Wu, H., Zheng, Z., Li, J., Qiu, C., Xu, P., Glaser, K. J., Murphy, M. C., Venkatesh, S. K., Yaqoob, U., Graham, R. P., et al. (2025) · Radiology · doi:10.1148/radiol.242349 · Cited by 16
NASHmap: clinical utility of a machine learning model to identify patients at risk of NASH in real-world settings
Schattenberg, J. M., Balp, M., Reinhart, B., Tietz, A., Régnier, S. A., Capkun, G., Ye, Q., Loeffler, J., Pedrosa, M. C., & Docherty, M. (2023) · Scientific Reports · doi:10.1038/s41598-023-32551-2 · Cited by 16
Sex-Specific Contribution of Cardiometabolic Index in Predicting Metabolic Dysfunction-Associated Fatty Liver Disease: Insights from a General Population
Gu, D., Lu, Y., Xu, B., & Tang, X. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s437413 · Cited by 17
SomaLogic proteomics reveals new biomarkers and provides mechanistic, clinical insights into Acetyl coA Carboxylase (ACC) inhibition in Non-alcoholic Steatohepatitis (NASH)
Sivakumar, P., Saul, M. E., Robinson, D., King, L. E., & Amin, N. B. (2024) · Scientific Reports · doi:10.1038/s41598-024-67843-8 · Cited by 17
Preparing for the NASH epidemic: A call to action
Kanwal, F., Shubrook, J. H., Younossi, Z. M., Natarajan, Y., Bugianesi, E., Rinella, M. E., Harrison, S. A., Mantzoros, C. S., Pfotenhauer, K. M., Klein, S., et al. (2021) · Obesity · doi:10.1002/oby.23250 · Cited by 18
Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A network meta-analysis
Ding, C., Tang, Y., Zhu, W., Huang, P., Lian, P., Ran, J., & Huang, X. (2022) · Acta Diabetologica · doi:10.1007/s00592-021-01830-7 · Cited by 16
Therapeutic Potentials of Reducing Liver Fat in Non-Alcoholic Fatty Liver Disease: Close Association with Type 2 Diabetes
Tsamos, G., Vasdeki, D., Koufakis, T., Michou, V., Makedou, K., & Tzimagiorgis, G. (2023) · Metabolites · doi:10.3390/metabo13040517 · Cited by 16
Binge drinking at time of bariatric surgery is associated with liver disease, suicides, and increases long-term mortality
Alvarado‐Tápias, E., Aguado, D. M., Gómez, C., Ferrero‐Gregori, A., Szafranska, J., Brujats, A., Osuna‐Gómez, R., Guinart-Cuadra, A., Alfaro‐Cervelló, C., Pose, E., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000490 · Cited by 16
Attenuation coefficient (ATT) measurement for liver fat quantification in chronic liver disease
Tamaki, N., Kurosaki, M., Yasui, Y., Tsuchiya, K., & Izumi, N. (2021) · Journal of Medical Ultrasonics · doi:10.1007/s10396-021-01103-4 · Cited by 15
Human Genetics to Identify Therapeutic Targets for NAFLD: Challenges and Opportunities
Du, X., DeForest, N., & Majithia, A. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.777075 · Cited by 17
Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonists
Shah, R. A., Alkhouri, N., & Kowdley, K. V. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1796968 · Cited by 15
Self-citation
Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial
Noureddin, M., Kowdley, K. V., Odrljin, T. M., Bain, G., Zhao, J., Jeglinski, B. I., Koziel, M. J., & Loomba, R. S. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02276-7 · Cited by 18
Self-citation
Nonalcoholic Fatty Liver Disease and the Risk of Thyroid Cancer Among Young Adults in South Korea
Kwon, H., Han, K., Moon, S. J., Park, S. E., Rhee, E., & Lee, W. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad575 · Cited by 14

Authors: Kleiner, D. E., Brunt, E. M., Wilson, L. A., Behling, C., Guy, C., Contos, M., Cummings, O., Yeh, M., Gill, R., Chalasani, N., Neuschwander-Tetri, B. A., Diehl, A. M., Dasarathy, S., Terrault, N., Kowdley, K., Loomba, R., Belt, P., Tonascia, J., Lavine, J. E., Sanyal, A. J., & for the Nonalcoholic Steatohepatitis Clinical Research Network
Affiliations: National Institutes of Health (US)
Washington University in St. Louis (US)
Johns Hopkins University (US)
University of California San Diego (US)
Duke University (US)
Virginia Commonwealth University (US)
Indiana University School of Medicine (US)
University of Washington (US)
University of California, San Francisco (US)
Indiana University Indianapolis (US)
Division of Gastroenterology, Saint Louis University School of Medicine, St Louis, Missouri
Cleveland Clinic (US)
University of Southern California (US)
Swedish Medical Center (US)
Columbia University Irving Medical Center (US)
Corresponding author: Kleiner, David E.
Sanyal, Arun J.
ORCID: Kleiner, David E.
Brunt, Elizabeth M.
Wilson, Laura A.
Behling, Cynthia
Guy, Cynthia
Cummings, Oscar
Yeh, Matthew
Gill, Ryan
Chalasani, Naga
Diehl, Anna Mae
Dasarathy, Srinivasan
Terrault, Norah
Kowdley, Kris
Loomba, Rohit
Tonascia, James
Lavine, Joel E.
Sanyal, Arun J.
Venue: JAMA Network Open
Publisher: American Medical Association (AMA)
Published: 2019-10-04
Volume: 2
Issue: 10
Pages: e1912565
ISSN: 2574-3805 (ISSN-L)
DOI: 10.1001/jamanetworkopen.2019.12565
PMC: PMC6784786
OpenAlex: W2977362851
Cited by: 372
References: 28
Citations by year: 2026: 32 · 2025: 53 · 2024: 48 · 2023: 66 · 2022: 62 · 2021: 65 · 2020: 44 · 2019: 2
FWCI: 32.92
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
Locations: JAMA Network Open (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
IUScholarWorks (Indiana University) (submittedVersion, cc-by)
Purdue University Indianapolis (Indiana University) (submittedVersion, cc-by)
Funders: National Institutes of Health (UL1TR000100, UL1TR000423, UL1TR000436, UL1TR000058, UL1TR000004, UL1TR000448, UL1TR000006, UL1TR000439, UL1TR002548, UL1TR001442, UL1TR002345, UL1TR002319)
National Institute of Diabetes and Digestive and Kidney Diseases (U01DK061730, U01DK061731, U01DK061713, U24DK061730, U01DK061728, U01DK061737, U01DK061732, U01DK061734, U01DK061718, U01DK061738)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords: non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, disease progression, fibrosis regression, NAFLD activity score, metabolic syndrome, steatosis, lobular inflammation, ballooning, liver biopsy
MeSH terms: Academic Medical Centers, Adult, Aspartate Aminotransferases, Female, Humans, Liver, Liver Cirrhosis, Male, Middle Aged, Risk Factors, United States, Cohort Studies, Weight Gain, Disease Progression, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks